Medicare Enrolled
Dr. Jessica Altman, MD
Hematology & Oncology · Chicago, IL
Practice pattern: Mixed Practice
— Diverse clinical practice across multiple procedure types
Consulting-driven
Very High
DATA COVERAGE
Data in 4 of 4 federal sources
Measures public federal data availability — not provider quality
Informational, not a quality rating.
This page presents federal public records about Dr. Altman from CMS (NPPES, Open Payments, Medicare Provider Utilization, PECOS). It is not medical advice, an endorsement, or a judgment of clinical quality. Always consult the provider directly and a licensed clinician for medical decisions. Read methodology →
Are you Dr. Altman?
Request a correction or review of any data shown here. Provider portal →
What this data tells you about Dr. Altman
Dr. Jessica Altman is a hematology & oncology specialist in Chicago, IL, with 19 years of NPI registration. Based on federal Medicare data, Dr. Altman performed 53,542 Medicare services across 1,277 unique beneficiaries.
Between the years covered by Open Payments, Dr. Altman received a total of $60,349 from 16 pharmaceutical and/or device companies across 88 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common in hematology & oncology. The majority of payments are for consulting, which typically reflects recognized clinical expertise sought by manufacturers. Patients may wish to discuss these relationships with their provider.
The Data Coverage level for Dr. Altman is Very High — reflecting how much public federal data is available about this provider. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.
✓ 19 years in practice
▲ Top 19% volume in IL
$60,349 industry payments
Medicare Practice Summary
Medicare Utilization ↗53,542
Medicare services
Top 19% in IL for hematology & oncology
1,277
Unique beneficiaries
$27
Avg. Medicare payment
Medicare patients only (65+ / disabled) · How to read this →
~2,818 Medicare services per year of practice
Top procedures by volume
Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.
| Procedure | Volume | Avg. paid | Avg. submitted |
|---|---|---|---|
| Nivolumab injection (Opdivo) | 14,544 | $24 | $97 |
| Daratumumab injection (Darzalex) An injection containing daratumumab and hyaluronidase-fihj administered under the skin. |
9,180 | $38 | $170 |
| Pembrolizumab injection (Keytruda) | 7,200 | $43 | $171 |
| Anti-nausea injection (fosaprepitant) An injection of fosaprepitant, a medication used to prevent nausea and vomiting. |
6,300 | $0 | $7 |
| Immune globulin infusion (Gammagard) An injection of immune globulin (Gammagard Liquid) to provide antibodies. The dose specified is 500 mg. |
3,110 | $35 | $134 |
| Carfilzomib injection, 1 mg This code represents the administration of a 1 mg dose of carfilzomib via injection. |
2,718 | $36 | $118 |
| Denosumab injection (Prolia/Xgeva) | 2,100 | $19 | $58 |
| Bortezomib injection, 0.1 mg Administration of a 0.1 mg dose of bortezomib medication via injection. |
1,749 | $3 | $174 |
| Bevacizumab biosimilar injection, 10 mg An injection of bevacizumab-awwb, a biosimilar medication, administered in a 10 mg dose. |
1,421 | $22 | $194 |
| Dexamethasone injection (steroid) An injection of dexamethasone sodium phosphate, a corticosteroid medication, administered in a dose of 1 milligram. |
938 | $0 | $1 |
| Anti-nausea injection (Aloxi/palonosetron) | 820 | $1 | $76 |
| Injection, atropine sulfate, 0.01 mg | 760 | $0 | $1 |
| Fluorouracil injection, 500 mg Administration of a 500 mg dose of fluorouracil medication via injection. |
369 | $2 | $8 |
| Pegfilgrastim injection, 0.5 mg An injection of pegfilgrastim, a medication that stimulates the production of white blood cells. This specific code applies to the brand-name drug and excludes biosimilar versions. |
312 | $77 | $821 |
| Methylprednisolone injection, up to 125 mg An injection of methylprednisolone sodium succinate, a corticosteroid medication, with a dosage of up to 125 mg. |
293 | $4 | $10 |
| Intravenous chemotherapy infusion, 1 hour or less Administration of chemotherapy medication directly into a vein. The procedure takes one hour or less to complete. |
223 | $108 | $940 |
| Intravenous injection of additional new drug or substance Administration of an additional new medication or substance directly into a vein. |
188 | $13 | $143 |
| Office visit, established patient, complex (40-54 min) An office or outpatient visit for an existing patient lasting between 40 and 54 minutes. This level of service is determined by the total time spent on the date of the encounter. |
180 | $137 | $434 |
| Office visit, established patient (30-39 min) A follow-up office visit for an existing patient lasting between 30 and 39 minutes. The visit involves medical evaluation and management of the patient's condition. |
142 | $98 | $323 |
| Additional hour of intravenous infusion This code represents each additional hour of intravenous infusion beyond the initial hour for therapy, prevention, or diagnosis. |
124 | $17 | $129 |
| Hospital follow-up visit, moderate complexity Follow-up hospital visit for an existing patient involving moderate medical decision making. The visit requires at least 35 minutes of time spent on the date of service. |
122 | $66 | $217 |
| Non-hormonal chemotherapy injection This procedure involves administering non-hormonal anti-neoplastic chemotherapy medication via injection into the skin or muscle tissue. |
113 | $60 | $326 |
| Additional sequential IV infusion, 1 hour or less This code represents an additional intravenous infusion administered sequentially to a primary infusion. It covers the administration time of one hour or less. |
110 | $24 | $203 |
| Drug injection, under skin or into muscle A procedure involving the administration of a medication or substance via injection into the subcutaneous tissue or muscle. |
78 | $12 | $88 |
| Intravenous infusion, 1 hour or less Administration of medication or fluid directly into a vein for therapeutic, preventive, or diagnostic purposes. The procedure lasts one hour or less. |
73 | $53 | $410 |
| Blood draw (venipuncture) Insertion of a needle into a vein to collect a blood sample. |
59 | $8 | $20 |
| Additional hour of intravenous chemotherapy This code represents the administration of chemotherapy medication into a vein for each additional hour beyond the initial period. |
56 | $23 | $215 |
| Intravenous infusion of new drug or substance, 1 hour or less This procedure involves administering a new medication or substance directly into a vein through an existing access site. The infusion is completed within one hour or less. |
45 | $53 | $464 |
| Hospital follow-up visit, high complexity Subsequent hospital inpatient or observation care for an existing patient involving high-level medical decision making, with at least 50 minutes total time on the date of the encounter. |
42 | $99 | $311 |
| IV chemotherapy initiation with community continuation Initiation of an intravenous chemotherapy infusion in a clinic using clinic supplies, with continuation of the infusion in a community setting such as home or assisted living. |
39 | $204 | $1,618 |
| Intravenous chemotherapy injection Chemotherapy medication is administered directly into a vein using a push technique. This method involves injecting the drug through a needle or catheter already placed in the vein. |
24 | $84 | $677 |
| Intravenous push injection of new drug or substance A healthcare provider injects a new medication or substance directly into a vein using a push technique. |
24 | $46 | $393 |
| Diphenhydramine injection, up to 50 mg An injection of diphenhydramine hydrochloride, an antihistamine medication, administered in a dose of up to 50 milligrams. |
20 | $1 | $4 |
| Hospital discharge day management, 30 minutes or less This service covers the final day of hospital care when the patient is being discharged. It includes coordination of care and instructions for the patient within a time frame of 30 minutes or less. |
15 | $67 | $216 |
| On-body injector for subcutaneous injection A device is applied to the skin to automatically deliver a medication injection under the skin. |
14 | $15 | $109 |
| Unclassified drug A medication that does not fit into standard HCPCS or CPT classification categories. |
14 | $2 | $12 |
| New patient office visit, complex (60-74 min) | 12 | $180 | $652 |
| Flu vaccine administration This procedure involves the administration of the influenza virus vaccine. It covers the process of delivering the vaccine to the patient. |
11 | $32 | $57 |
How to read this data: This reflects Medicare patients only (typically 65+). Payment amounts are what Medicare paid the provider, not your out-of-pocket cost. A higher procedure volume generally indicates more experience with that procedure.
6.9% high complexity
92.0% medium
1.1% routine
Industry Payment Transparency
Open Payments through 2024 ↗$60,349
Total received (2018-2024)
Avg $10,058/year across 6 years
Top 12% in IL for hematology & oncology
A higher payment rank reflects disclosed industry relationships (consulting, research, speaking) common among subspecialists — not wrongdoing.
16
Companies
88
Individual payments
All payments are legal and publicly reported · Not evidence of wrongdoing · How to interpret →
Payment profile
Industry payments classified by relationship type. Not all payments are equal — research and consulting reflect different relationships than speaking programs or meals.
Consulting
Expert advisory fees, typically reflecting recognized clinical expertise
$34,101 (56.5%)
Meals & Travel
Food, beverages, travel, and lodging — typically low-value
$15,718 (26.0%)
Speaking / Promotional
Speaker programs, honoraria, and industry-sponsored educational events
$10,530 (17.4%)
Payment trend by year
Annual totals from pharmaceutical and medical device companies.
2024
$17,034
2023
$15,472
2022
$1,367
2021
$3,489
2019
$19,181
2018
$3,805
Payments by company (2024)
Consulting
Speaking
Meals & Travel
Research
Astellas Pharma Europe Ltd
$11,722
Daiichi Sankyo Inc.
$4,623
Astellas Pharma US Inc
$237
ABBVIE INC.
$150
JAZZ PHARMACEUTICALS INC.
$143
Astellas Pharma Inc
$59
Celgene Corporation
$55
Genentech USA, Inc.
$44
Top 3 companies account for 97.3% of 2024 payments
All-time payments by company (2018-2024) ›
Daiichi Sankyo Inc.
$16,500
AbbVie, Inc.
$12,856
Astellas Pharma Europe Ltd
$11,722
Astellas Pharma Global Development
$4,006
Servier Pharmaceuticals LLC
$3,472
Gilead Sciences, Inc.
$3,062
Novartis Pharmaceuticals Corporation
$2,730
Agios Pharmaceuticals, Inc.
$2,356
Celgene Corporation
$1,005
Stemline Therapeutics Inc.
$975
Astellas Pharma US Inc
$872
Genentech USA, Inc.
$300
JAZZ PHARMACEUTICALS INC.
$274
ABBVIE INC.
$150
Astellas Pharma Inc
$59
Acrotech Biopharma LLC
$12
Top 3 companies account for 68.1% of all-time payments
Associated products mentioned in payments ›
ABL002 · BELEODAQ · DEFITELIO · ELZONRIS · ONUREG · REBLOZYL · RYLAZE · TIBSOVO · VENCLEXTA · Vanflyta · Venclexta · XOSPATA · Xospata
Should you be concerned? Payments from pharmaceutical and device companies are legal and common — 57% of U.S. physicians receive at least one. They often reflect legitimate consulting, research, or education. What matters is whether a recommended drug or device appears in your doctor's payment records. If so, consider asking your doctor about it. How to interpret this data →
The majority of payments (56%) are consulting fees, which typically reflect recognized clinical expertise sought by manufacturers.
Geographic Context
Hematology & oncology specialists within 10 mi
326
Per 100K population
6.3
County median income
$81,797
Nearest hospital
NORTHWESTERN MEMORIAL HOSPITAL
0.0 mi
0.0 mi
Data Sources
| Provider Registry | ✓ NPPES | Weekly updates |
| Medicare Enrollment | ✓ PECOS | Monthly updates |
| Practice Data | ✓ Medicare Util. | Annual (CY lag) |
| Industry Payments | ✓ Open Payments | CY 2024 |
| Disciplinary History | — Not public | N/A |
This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This reflects how much public data is available about a provider. How we calculate this →
Summary
Dr. Altman is a mixed practice specialist, with above-average Medicare volume (top 19% in IL), with consulting-driven industry engagement in the top 12% of IL peers, with 19 years of NPI registration.
This summary is auto-generated from federal data, describing data availability and patterns. Read our methodology →
Frequently Asked Questions
Is Dr. Altman experienced with nivolumab injection (opdivo)?
Based on Medicare claims data, Dr. Altman performed 14,544 nivolumab injection (opdivo) services. Research suggests that higher procedure volume is often associated with better outcomes, particularly for complex procedures. Note that Medicare data only captures patients aged 65 and older, so the total practice volume across all patients is likely higher.
Does Dr. Altman receive payments from pharmaceutical companies?
Yes. Dr. Altman received a total of $60,349 from 16 companies across 88 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common among physicians — 57% of all U.S. physicians receive at least one industry payment. Patients may wish to ask their doctor about these relationships, especially if a recommended drug or device appears in the payment records.
How do Dr. Altman's costs compare to other hematology & oncology specialists in Chicago?
Dr. Altman's average Medicare payment per service is $27. Note that these figures represent what Medicare pays, not your out-of-pocket cost, which depends on your specific insurance plan and deductible. Procedure-level data above shows both what was submitted and what Medicare paid for each service type.
What does Data Coverage mean?
Data Coverage (currently Very High for Dr. Altman) measures how much public federal data is available about a provider. It is not a quality rating. A "Very High" or "High" level means the provider has data across multiple federal sources (NPPES, PECOS, Medicare Utilization, Open Payments), indicating a long track record of practice, Medicare participation, and industry disclosure. A "Low" or "Moderate" level may simply mean the provider is newer, does not see Medicare patients, or has not received any industry payments — none of which are inherently negative. Read our full methodology →
Is this data up to date?
Each data source has its own update cycle. Provider registry data (NPPES) is updated weekly. Medicare enrollment (PECOS) is updated monthly. Medicare practice data has a ~2 year lag — the most recent available is typically 2 years prior. Industry payment data (Open Payments) is published annually, usually in June, covering the prior calendar year. We display the data date prominently on each section so you always know how current it is. See our data freshness policy →
Explore related providers
Same specialty & city
Hematology & Oncology Specialists in Chicago
Browse hematology & oncology specialists in Chicago ranked by procedure volume and transparency data.
Highest volume
Top Hematology & Oncology Specialists in IL
Hematology & oncology specialists ranked by total Medicare services performed statewide.
Industry payments
Pharma Payments to Hematology & Oncology Specialists in IL
Which IL hematology & oncology specialists receive the most from drug and device companies.
By company
Daiichi Sankyo Inc. Payments to Doctors
See all physicians who received payments from Daiichi Sankyo Inc.
By company
AbbVie, Inc. Payments to Doctors
See all physicians who received payments from AbbVie, Inc.
By company
Astellas Pharma Europe Ltd Payments to Doctors
See all physicians who received payments from Astellas Pharma Europe Ltd.
About this page
All data on this page is sourced verbatim from public federal records published by the U.S. Centers for Medicare & Medicaid Services (CMS): NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.
This page is not medical advice, an endorsement, a recommendation, or a quality rating. Data Coverage reflects data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.
Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology